Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors

Eitaro Kodani, Ken Shinmura, Yu Ting Xuan, Hitoshi Takano, John A. Auchampach, Xian Liang Tang, Roberto Bolli

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Recent studies have demonstrated that the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and the adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA) produce a delayed phase of protection against infarction similar to the late phase of ischemic preconditioning (PC). However, the mechanism for adenosine A1 or A3 receptor-induced late PC remains unknown. The goal of this study was to determine whether the delayed cardioprotective effects of adenosine A1 or A3 receptors are mediated by cyclooxygenase-2 (COX-2), which is an obligatory mediator of ischemic PC. We found that COX-2 protein expression (Western blotting) did not increase 24 h after the administration of either CCPA (100 μg/kg iv) or IB-MECA (300 μg/kg iv) compared with controls. To probe the role of constitutive COX-2 expression, conscious rabbits were subjected to 30-min coronary occlusion followed by 72-h reperfusion. Twenty-four hours before the occlusion, the rabbits were pretreated with CCPA (100 μg/kg iv) or IB-MECA (300 μg/kg iv). Both CCPA and IB-MECA resulted in a marked (∼47%) reduction in infarct size vs. controls [36.2 ± 4.0% of the risk region (n = 9), 31.2 ± 4.7% (n = 9), and 59.5 ± 3.8% (n = 9), respectively; P < 0.05], similar to that induced by the late phase of ischemic PC [31.8 ± 3.2% (n = 9)]. The selective COX-2 inhibitor N-(2-[cyclohexyloxy]4-nitrophenyl)methanesulfonamide (NS-398, 5 mg/kg), which abolished the protective effect of ischemic late PC, failed to block the protection of either CCPA or IB-MECA, indicating that COX-2 does not mediate the delayed protection of either CCPA or IB-MECA [CCPA + NS-398, 29.1 ± 3.4% (n = 7); IB-MECA + NS-398, 34.9 ± 2.9% (n = 8)]. NS-398 in itself did not affect infarct size [54.9 ± 3.7% (n = 9)]. Taken together, these results demonstrate that, in contrast to ischemia-induced late PC, the mechanisms of adenosine A1 or A3 receptor-induced late PC is independent of COX-2.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume281
Issue number2 50-2
Publication statusPublished - 2001

Fingerprint

Adenosine A3 Receptors
Adenosine A1 Receptors
Cyclooxygenase 2
Ischemic Preconditioning
Adenosine A3 Receptor Agonists
Adenosine A1 Receptor Agonists
Rabbits
Cyclooxygenase 2 Inhibitors
Coronary Occlusion
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
N(6)-cyclopentyladenosine
Adenosine
Infarction
Reperfusion
Ischemia
Western Blotting
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide

Keywords

  • 2-chloro-N-cyclopentyl-adenosine
  • Myocardial ischemia
  • Myocardial reperfusion
  • N -(3-iodobenzyl)adenosine-5′-N-methyluronamide
  • NS-398

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Kodani, E., Shinmura, K., Xuan, Y. T., Takano, H., Auchampach, J. A., Tang, X. L., & Bolli, R. (2001). Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors. American Journal of Physiology - Heart and Circulatory Physiology, 281(2 50-2).

Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors. / Kodani, Eitaro; Shinmura, Ken; Xuan, Yu Ting; Takano, Hitoshi; Auchampach, John A.; Tang, Xian Liang; Bolli, Roberto.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 281, No. 2 50-2, 2001.

Research output: Contribution to journalArticle

Kodani, Eitaro ; Shinmura, Ken ; Xuan, Yu Ting ; Takano, Hitoshi ; Auchampach, John A. ; Tang, Xian Liang ; Bolli, Roberto. / Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors. In: American Journal of Physiology - Heart and Circulatory Physiology. 2001 ; Vol. 281, No. 2 50-2.
@article{6b105a567f36466c811fe09a169b3dc2,
title = "Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors",
abstract = "Recent studies have demonstrated that the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and the adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA) produce a delayed phase of protection against infarction similar to the late phase of ischemic preconditioning (PC). However, the mechanism for adenosine A1 or A3 receptor-induced late PC remains unknown. The goal of this study was to determine whether the delayed cardioprotective effects of adenosine A1 or A3 receptors are mediated by cyclooxygenase-2 (COX-2), which is an obligatory mediator of ischemic PC. We found that COX-2 protein expression (Western blotting) did not increase 24 h after the administration of either CCPA (100 μg/kg iv) or IB-MECA (300 μg/kg iv) compared with controls. To probe the role of constitutive COX-2 expression, conscious rabbits were subjected to 30-min coronary occlusion followed by 72-h reperfusion. Twenty-four hours before the occlusion, the rabbits were pretreated with CCPA (100 μg/kg iv) or IB-MECA (300 μg/kg iv). Both CCPA and IB-MECA resulted in a marked (∼47{\%}) reduction in infarct size vs. controls [36.2 ± 4.0{\%} of the risk region (n = 9), 31.2 ± 4.7{\%} (n = 9), and 59.5 ± 3.8{\%} (n = 9), respectively; P < 0.05], similar to that induced by the late phase of ischemic PC [31.8 ± 3.2{\%} (n = 9)]. The selective COX-2 inhibitor N-(2-[cyclohexyloxy]4-nitrophenyl)methanesulfonamide (NS-398, 5 mg/kg), which abolished the protective effect of ischemic late PC, failed to block the protection of either CCPA or IB-MECA, indicating that COX-2 does not mediate the delayed protection of either CCPA or IB-MECA [CCPA + NS-398, 29.1 ± 3.4{\%} (n = 7); IB-MECA + NS-398, 34.9 ± 2.9{\%} (n = 8)]. NS-398 in itself did not affect infarct size [54.9 ± 3.7{\%} (n = 9)]. Taken together, these results demonstrate that, in contrast to ischemia-induced late PC, the mechanisms of adenosine A1 or A3 receptor-induced late PC is independent of COX-2.",
keywords = "2-chloro-N-cyclopentyl-adenosine, Myocardial ischemia, Myocardial reperfusion, N -(3-iodobenzyl)adenosine-5′-N-methyluronamide, NS-398",
author = "Eitaro Kodani and Ken Shinmura and Xuan, {Yu Ting} and Hitoshi Takano and Auchampach, {John A.} and Tang, {Xian Liang} and Roberto Bolli",
year = "2001",
language = "English",
volume = "281",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "2 50-2",

}

TY - JOUR

T1 - Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors

AU - Kodani, Eitaro

AU - Shinmura, Ken

AU - Xuan, Yu Ting

AU - Takano, Hitoshi

AU - Auchampach, John A.

AU - Tang, Xian Liang

AU - Bolli, Roberto

PY - 2001

Y1 - 2001

N2 - Recent studies have demonstrated that the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and the adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA) produce a delayed phase of protection against infarction similar to the late phase of ischemic preconditioning (PC). However, the mechanism for adenosine A1 or A3 receptor-induced late PC remains unknown. The goal of this study was to determine whether the delayed cardioprotective effects of adenosine A1 or A3 receptors are mediated by cyclooxygenase-2 (COX-2), which is an obligatory mediator of ischemic PC. We found that COX-2 protein expression (Western blotting) did not increase 24 h after the administration of either CCPA (100 μg/kg iv) or IB-MECA (300 μg/kg iv) compared with controls. To probe the role of constitutive COX-2 expression, conscious rabbits were subjected to 30-min coronary occlusion followed by 72-h reperfusion. Twenty-four hours before the occlusion, the rabbits were pretreated with CCPA (100 μg/kg iv) or IB-MECA (300 μg/kg iv). Both CCPA and IB-MECA resulted in a marked (∼47%) reduction in infarct size vs. controls [36.2 ± 4.0% of the risk region (n = 9), 31.2 ± 4.7% (n = 9), and 59.5 ± 3.8% (n = 9), respectively; P < 0.05], similar to that induced by the late phase of ischemic PC [31.8 ± 3.2% (n = 9)]. The selective COX-2 inhibitor N-(2-[cyclohexyloxy]4-nitrophenyl)methanesulfonamide (NS-398, 5 mg/kg), which abolished the protective effect of ischemic late PC, failed to block the protection of either CCPA or IB-MECA, indicating that COX-2 does not mediate the delayed protection of either CCPA or IB-MECA [CCPA + NS-398, 29.1 ± 3.4% (n = 7); IB-MECA + NS-398, 34.9 ± 2.9% (n = 8)]. NS-398 in itself did not affect infarct size [54.9 ± 3.7% (n = 9)]. Taken together, these results demonstrate that, in contrast to ischemia-induced late PC, the mechanisms of adenosine A1 or A3 receptor-induced late PC is independent of COX-2.

AB - Recent studies have demonstrated that the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and the adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA) produce a delayed phase of protection against infarction similar to the late phase of ischemic preconditioning (PC). However, the mechanism for adenosine A1 or A3 receptor-induced late PC remains unknown. The goal of this study was to determine whether the delayed cardioprotective effects of adenosine A1 or A3 receptors are mediated by cyclooxygenase-2 (COX-2), which is an obligatory mediator of ischemic PC. We found that COX-2 protein expression (Western blotting) did not increase 24 h after the administration of either CCPA (100 μg/kg iv) or IB-MECA (300 μg/kg iv) compared with controls. To probe the role of constitutive COX-2 expression, conscious rabbits were subjected to 30-min coronary occlusion followed by 72-h reperfusion. Twenty-four hours before the occlusion, the rabbits were pretreated with CCPA (100 μg/kg iv) or IB-MECA (300 μg/kg iv). Both CCPA and IB-MECA resulted in a marked (∼47%) reduction in infarct size vs. controls [36.2 ± 4.0% of the risk region (n = 9), 31.2 ± 4.7% (n = 9), and 59.5 ± 3.8% (n = 9), respectively; P < 0.05], similar to that induced by the late phase of ischemic PC [31.8 ± 3.2% (n = 9)]. The selective COX-2 inhibitor N-(2-[cyclohexyloxy]4-nitrophenyl)methanesulfonamide (NS-398, 5 mg/kg), which abolished the protective effect of ischemic late PC, failed to block the protection of either CCPA or IB-MECA, indicating that COX-2 does not mediate the delayed protection of either CCPA or IB-MECA [CCPA + NS-398, 29.1 ± 3.4% (n = 7); IB-MECA + NS-398, 34.9 ± 2.9% (n = 8)]. NS-398 in itself did not affect infarct size [54.9 ± 3.7% (n = 9)]. Taken together, these results demonstrate that, in contrast to ischemia-induced late PC, the mechanisms of adenosine A1 or A3 receptor-induced late PC is independent of COX-2.

KW - 2-chloro-N-cyclopentyl-adenosine

KW - Myocardial ischemia

KW - Myocardial reperfusion

KW - N -(3-iodobenzyl)adenosine-5′-N-methyluronamide

KW - NS-398

UR - http://www.scopus.com/inward/record.url?scp=0034880998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034880998&partnerID=8YFLogxK

M3 - Article

VL - 281

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 2 50-2

ER -